We empower our customers to achieve a mastery of biology with software that transforms biological data into knowledge and actionable insights
Biomatters was founded in 2003 with a mission to create bioinformatics solutions for the analysis, interpretation, and application of molecular sequence data.
Headquartered in New Zealand with offices in the United States and Denmark, and users in more than 100 countries worldwide, our solutions enhance productivity in over 3,000 universities, research institutes and companies.
We specialize in creating powerful, integrated and visually appealing bioinformatics solutions, with a strong emphasis on ease of use and overall user experience.
Dedicated to excellence
Our solutions have won a number of prestigious awards, including:
- 2007 – Computerworld Excellence Awards for Innovative Use of ICT
- 2007 – United Nations World Summer Awards and Winner in the e-Science Category
- 2009 – Recruit IT Innovative Software Product Award at the PriceWaterhouseCoopers Hi-Tech Awards
- 2009 – Global Finalist in the IT and Informatics category at the Bio-IT World Awards in Boston
- 2012 – Microsoft Hi-Tech Emerging Company Award
- 2015 – Best of Show Finalist at the Bio-IT World Awards in Boston
A powerful and comprehensive suite of molecular biology and NGS analysis tools
First released in 2005, Geneious is one the world’s leading bioinformatics software platforms, used by over 3,000 universities and institutes and commercial companies in more than 100 countries.
Geneious is used by all 20 of the top 20 universities globally (Times Higher Education, 2016) and by 16 of the 20 largest pharmaceutical companies.
Further information at www.geneious.com
A next-generation cloud solution purpose-built for commercial antibody discovery and screening
Geneious Biologics has been specifically designed and purpose-built, in collaboration with industry partners, as an enterprise solution for commercial antibody discovery and screening. The platform is flexible and customizable to integrate with specific customer data requirements and workflows.
Delivered through a modern intuitive, user-friendly web interface, the platform provides a fully managed data platform and informatics system in a secure cloud computing infrastructure. The architecture of the software delivers scalable data management and computation, enabling organizations to increase their process efficiencies and thus accelerate their drug discovery.
Further information at www.geneiousbiologics.com
Andrew Steel, Chief Executive Officer
Andrew is a professional executive who blends strong commercial and operational skills with a depth of experience across a range of industries, including financial, manufacturing and retail sectors. He holds a law degree from Cambridge University in the UK, and gained additional financial and regulatory education during a period working in the City of London.
Chris Duran, Chief Technology Officer
Chris is skilled in identifying industry trends and defining products that meet the needs of users in the biotechnology space. He is responsible for executive leadership of the product and technology teams. He holds a PhD in bioinformatics from the University of Queensland.
Brett Ammundsen, President
After gaining his PhD in chemistry and physics from Victoria University in Wellington, New Zealand, Brett worked as a research scientist in Montpellier, France, specializing in solid state molecular dynamics and computer modelling. He then returned to New Zealand to help incubate technology start-up businesses focusing on scientific applications. He has published more than 25 peer-reviewed papers and is co-author of several patents.